The Technical Analyst
AnaptysBio Inc [ANAB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
AnaptysBio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.20% $19.87
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 531.78 mill |
| EPS: | -6.08 |
| P/E: | -3.27 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 26.76 mill |
| Avg Daily Volume: | 0.325 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.27 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.56x |
| Company: PE -3.27 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-14.02 (-170.57%) $-33.89 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 18.47 - 21.25 ( +/- 7.01%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-22 | Faga Daniel | Sell | 145 940 | Common Stock |
| 2024-03-25 | Faga Daniel | Sell | 3 000 | Common Stock |
| 2024-03-26 | Faga Daniel | Sell | 347 441 | Common Stock |
| 2024-02-16 | Loumeau Eric J | Sell | 5 000 | Employee Stock Option (right to buy) |
| 2024-02-16 | Loumeau Eric J | Buy | 5 000 | Common Stock |
| INSIDER POWER |
|---|
| 37.56 |
| Last 98 transactions |
| Buy: 3 215 504 | Sell: 1 263 529 |
Forecast:
16:00 - $19.86
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $19.86
Forecast 2: 16:00 - $19.86
Forecast 3: 16:00 - $19.86
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $19.87 (0.20% ) |
| Volume | 0.282 mill |
| Avg. Vol. | 0.325 mill |
| % of Avg. Vol | 86.76 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ANAB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $23.34 | N/A | Active |
|---|
ANAB
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Latest Press Releases
2024-03-11 16:15:00 - Press Release
Anaptys Announces Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
San diego, march 11, 2024 (globe newswire) -- anaptysbio, inc. (nasdaq: anab), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended december 31, 2023 and provided a business update.
2024-02-29 09:15:00 - Press Release
Anaptys To Present At Td Cowen's 44th Annual Health Care Conference And 2024 Aad Annual Meeting
San diego, feb. 29, 2024 (globe newswire) -- anaptysbio, inc. (nasdaq: anab), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that daniel faga, president and chief executive officer, will participate in a panel discussion at td cowen's 44th annual health care conference.
2024-01-31 09:15:00 - Press Release
Anaptys To Present At Guggenheim's 6th Annual Biotechnology Conference
San diego, jan. 31, 2024 (globe newswire) -- anaptysbio, inc. (nasdaq: anab), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that daniel faga, president and chief executive officer, will present at guggenheim's 6th annual biotechnology conference.
2023-11-27 16:15:00 - Press Release
Anaptys Expands Immune Cell Modulator Pipeline With Exclusive License To bdca2 Modulator Antibody Portfolio From Centessa Pharmaceuticals
San diego, nov. 27, 2023 (globe newswire) -- anaptysbio, inc. (nasdaq: anab), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclusive license agreement for centessa pharmaceuticals' (nasdaq: cnta) blood dendritic cell antigen 2 (bdca2) modulator antibody portfolio, including lead asset cbs004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases. anaptys anticipates filing an ind application for cbs004, which will be renamed anb101, in h2 2024.
2023-11-07 16:15:00 - Press Release
Anaptys Named A Biospace 2024 Best Places To Work Winner
San diego, nov. 07, 2023 (globe newswire) -- anaptysbio, inc. (nasdaq: anab), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for the second year in a row, it has been named a biospace 2024 best place to work in the small employer category.
Latest News
2024-04-15 14:19:53 - InvestorPlace
BTIG Research Predicts Over 118% Rally for These 3 Stocks
The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ: SMCI ) leading the way with a 216% gain so far.
2024-04-12 19:00:50 - The Motley Fool
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A major bank initiated coverage of the biotech. It recommended a buy, speculating that the share price could double and then some.
2024-04-09 15:41:04 - Zacks Investment Research
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-03-14 13:01:07 - Zacks Investment Research
What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock
AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-14 10:56:04 - Zacks Investment Research
Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade
The mean of analysts' price targets for AnaptysBio, Inc. (ANAB) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-03-11 18:31:05 - Zacks Investment Research
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.59 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to loss of $0.93 per share a year ago.
2024-02-29 09:15:00 - GlobeNewsWire
Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen's 44th Annual Health Care Conference.
2024-02-28 11:00:22 - Zacks Investment Research
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
AnaptysBio, Inc. (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-19 06:56:03 - Zacks Investment Research
Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?
AnaptysBio, Inc. (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-01-31 09:15:00 - GlobeNewsWire
Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim's 6th Annual Biotechnology Conference.